Submission of financial results for the quarter ended 30th September 2025.

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.9%Reaction day

₹95.00

prior close

₹98.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-6.5% vs market

Pharmaceuticals peers, median of 157sector+0.1%-6.0% vs sector

On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 6.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-4.2

10m

-1.6

15m

-1.6

30m

-4.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.9+0.6-6.5+0.1-6.0

Next day

-5.8-0.2-5.6-0.7-5.1

-7.4-0.4-7.0-1.1-6.3

-9.4-0.7-8.7-0.9-8.6

-6.4-2.2-4.2-1.9-4.5

-9.9-2.8-7.1-3.1-6.8

-12.2-1.4-10.8-2.1-10.1

15d

-14.7-7.0-7.7-4.7-10.0

-6.3-6.1-0.2-5.0-1.3

-8.9-9.2+0.3-7.6-1.4

-21.2-6.8-14.3-9.5-11.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astal Laboratories reported revenue from operations of Rs 3,751.64 lakhs for Q2 FY26, up sharply from Rs 1,315.98 lakhs in Q2 FY25, driven by its Bulk Drugs/APIs business. Total income for the half year rose to Rs 6,293.18 lakhs versus Rs 2,633.97 lakhs in H1 FY25, roughly a 139% jump. Profit after tax for the quarter stood at Rs 258.26 lakhs (vs Rs 200.29 lakhs, up ~29% YoY) and H1 PAT was Rs 467.22 lakhs (vs Rs 369.20 lakhs, up ~27%). Basic EPS for the quarter was Rs 2.40. The auditor (Sathuluri & Co) issued an unmodified limited review report with no qualifications.

Likely market impact

Strong top-line growth and rising profits are positive for shareholders, but operating cash flow turned negative at Rs (164.10) lakhs in H1 FY26 and margins compressed sharply, signalling that profitability gains lag the revenue surge. Watch working capital and cash conversion in coming quarters.